新型口服抗凝药的药物基因组学研究进展  

Advances in pharmacogenomics of new oral anticoagulants

作　　者：陈安妮 范成龙[1] 范国荣 李琴[1] CHEN An-ni;FAN Cheng-long;FAN Guo-rong;LI Qin(Department of Clinical Pharmacy,Shanghai General Hospital,Shanghai Jiao Tong University,Shanghai 200080,China;Department of Pharmacy,Eastern Hepatobiliary Surgery Hospital,Naval Medical University(Second Military Medical University),Shanghai 200438,China)

机构地区：[1]上海交通大学附属第一人民医院临床药学室,上海200080 [2]海军军医大学(第二军医大学)东方肝胆外科医院药材科,上海200438

出　　处：《第二军医大学学报》2020年第5期558-563,共6页Academic Journal of Second Military Medical University

基　　金：上海交通大学医工交叉研究基金面上项目(YG2017MS29).

摘　　要：新型口服抗凝药(NOAC)在心脑血管血栓疾病的防治中发挥了重要作用。由于参与NOAC体内过程的转运体和代谢酶的基因多态性,不同个体口服相同剂量的NOAC后,其体内药代动力学参数存在差异。相对于药物转运体,药物代谢酶的基因多态性对NOAC的药代动力学性质影响较大,但目前相关研究较少。本文分析总结了基因多态性对NOAC药代动力学性质的影响。Novel oral anticoagulants(NOACs)play an important role in the prevention and treatment of cardiovascular and cerebrovascular thrombosis.Different individuals have different pharmacokinetic parameters in vivo after taking the same dose of NOACs,which may be related to gene polymorphisms of transporters and metabolic enzymes involved in the in vivo process of NOACs.Compared with drug transporters,gene polymorphisms of drug metabolizing enzymes have a greater impact on the pharmacokinetic properties of NOACs,but there have been few related studies up to now.In this paper we summarized the effects of gene polymorphisms on the pharmacokinetic properties of NOACs.

关 键 词：新型口服抗凝药 药物基因组学 转运系统 代谢酶类 药代动力学 基因多态性 

分 类 号：R973.2[医药卫生—药品]